CHI2 Antibody
Description
Antibody Nomenclature and Possible Interpretations
Antibodies are typically named based on their target antigen, type (e.g., monoclonal, polyclonal), or clinical application. For example:
-
Anti-CHIKV-E2 mAbs: Target the E2 envelope protein of Chikungunya virus (e.g., antibody 19-1) .
-
Meplazumab: A monoclonal antibody targeting CD147 for COVID-19 treatment .
The term "CHI2" might:
-
Refer to a statistical term: The χ² (chi-square) test is used to analyze contingency tables in antibody-related studies (e.g., testing antibody specificity) .
-
Be a misrepresentation: For example, "CHIKV" (Chikungunya virus) antibodies are well-documented , while "CHI2" is not.
Therapeutic Antibodies
Diagnostic Antibodies
Validation and Quality Control
A large-scale study tested 614 commercial antibodies across 65 proteins, revealing:
-
Performance: ~50% failed in ≥1 application (WB, IP, IF); recombinant antibodies outperformed polyclonal ones .
-
Coverage: ~50–75% of proteins had high-performing antibodies, depending on application .
Statistical Analysis
Challenges and Future Directions
-
Cross-Reactivity: Commercial antibodies often bind non-target antigens, necessitating rigorous validation .
-
Therapeutic Limitations: Mouse-derived antibodies trigger immune responses; humanized versions address this .
-
Diagnostic Innovations: ATR-FTIR spectroscopy and machine learning models improve autoantibody detection .
